Anti-Mouse/Human GL7 – FITC

Anti-Mouse/Human GL7 – FITC

Product No.: G222

- -
- -
Clone
GL7
Target
GL7
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
Ly77, T and B cell activation marker
Isotype
Rat IgM κ
Applications
ELISA
,
FC
,
IHC
,
IP
,
WB
,
MACS

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse/Human
Host Species
Rat
Immunogen
LPS activated DBA/J mouse B cells
Product Concentration
0.2 mg/ml
Formulation
This Fluorescein (FITC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
State of Matter
Liquid
Storage and Handling
This Fluorescein conjugate is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Excitation Laser
Blue Laser (488 nm)
Additional Applications Reported In Literature ?
ELISA,
FC,
IHC,
IP,
MACS,
WB
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
GL7 (aka Ly77) is an antiglycan antibody that recognizes α2,6-linked Sia-containing glycan chains found on N-glycans of various proteins.
Background
GL7 antibody was originally used in mouse to identify a 35 kDa cell surface protein expressed selectively on subpopulations of activated B and T cells as well as discrete subpopulations of T and B lineage cells in vivo 1GL7 antibody was originally used in mouse to identify a 35 kDa cell surface protein expressed selectively on subpopulations of activated B and T cells as well as discrete subpopulations of T and B lineage cells in vivo1. GL7 recognizes a glycan moiety containing a terminal sialic acid (Sia)2. Determinant recognition by GL7 is specific to Neu5Ac-bearing glycans, which is a Sia modification at the C-5 position.

GL7 reactivity has been assessed against various mouse and human B cell lines2. In mouse bone marrow, GL7 first appears on the cell surface of B220+CD117+ pro-B cells and then peaks at the B220+CD40- pro-B/pre-B-I transition, with expression decreasing slightly after the pre-B-I phase3,4. GL7 expression remains high on pre-B-II and immature B cells but is almost completely downregulated on mature B cells3. This phenotype is independent of mouse genetic background. In contrast, thymic GL7 expression differs between BALB/c and C57BL/6 strains5.

GL7 has stronger reactivity against human B cell lines than mouse B cell lines2. Staining patterns show that the GL7 epitope on Daudi cells is similar to that of mouse activated B cells and is inhibited by broad sialidase treatment but not treatment specific to α2,3-linked Sia. Differences in GL7 epitope expression, caused by differential expression of enzymes involved in the biosynthesis of the GL7 epitope glycan, rather than differences in carrier protein expression, leads to variable staining in human B cell lines. ST6GAL1 has the strongest correlation with the GL7 staining profile.

Antigen Distribution
GL7 binds to cell surface proteins expressed selectively on subpopulations of activated mouse B cells, CD4+, and CD8+ T cells as well as germinal centers in KLH immunized spleen or lymph nodes. GL7 also binds some thymocytes (CD4+CD8-) and B220+ cells as well as large pre-B cells in bone marrow. Additionally, GL7 is expressed on germinal center B cells, some neuronal cell types, choroid plexus epithelial cells, and some B cells derived from spleen, lymph node, peritoneal cavity, liver, and peripheral blood.
Ligand/Receptor
Neu5Ac-recognizing lectins
Research Area
Immunology
.
Innate Immunity

References & Citations

1.Laszlo G, Hathcock KS, Dickler HB, et al. J Immunol.150(12):5252-5262. 1993.
2 Naito Y, Takematsu H, Koyama S, et al. Mol Cell Biol. 27(8):3008-3022. 2007.
3 Cervenak L, Magyar A, Boja R, et al. Immunol Lett. 78(2):89-96. 2001.
4 Murasawa M, Okada S, Obata S, et al. Eur J Immunol. 32(1):291-298. 2002.
5 Hathcock KS, Pucillo CE, Laszlo G, et al. J Immunol. 155(10):4575-4581. 1995.
Indirect Elisa Protocol
Flow Cytometry
IHC
Immunoprecipitation Protocol
General Western Blot Protocol
MACS

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.